Vascular Disrupting Agents Market, 2021-2030: Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Liver Cancer, Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Renal Pelvis and Ureter Cancer), Therapeutic Area (Hematological Malignancies, Solid Tumors), Molecules (Tubulin Binding Agents, Flavonoids and Ligand-Directed Agents), Therapy (Mono and Combination), Route of Administration (Oral, Intravenous), and Regions (North America, Europe, Asia-Pacific and RoW)

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2021

  • Pages

  • View Count

Request Sample Pages


USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases